Fig. 1

The relationship between copy number of miR-3613 and breast cancer subtypes and survival rate. a Left: Proportion description of diverse groups in breast cancer patients distinguished by their genomic copy number values (CNVs) of MIR3613 from TCGA database. Homozygous deletion or single copy deletion (CNV < 0) represented as deletion group, diploid normal copy (CNV = 0) represented as normal group, low-level copy amplification or high-level copy amplification (CNV > 0) represented as amplification group. Right: Proportion description of diverse groups in breast cancer cell lines distinguished by the MIR3613 CNV from Cancer Cell Line Encyclopedia (CCLE). b The CNVs of MIR3613, RB1 and BRCA2 in breast cancer patients from TCGA database. c MIR3613 CNV profiles in breast cancer subtypes from TCGA database. Different breast cancer subtypes contained diverse non-deletion (high-CNV) or deletion (low-CNV) patients’ distribution indicated by the Pearson chi-squared test (P < 0.001). Luminal A, n = 224; Luminal B, n = 127; HER2-enriched, n = 56; Basal-like, n = 92. d Kaplan–Meier survival curves of ER-positive breast cancer patients from TCGA database were depicted by MIR3613 CNVs (P = 0.02). The non-deletion group contained samples with high-CNV of MIR3613 (CNV ≥ 0, n = 215), while the deletion group contained samples with low-CNV of MIR3613 (CNV < 0, n = 173)